Effects of the 2022 Reconciliation Act's Drug Provisions: What Have We Learned So Far and What Questions Remain?
Presentation
Presentation by Austin Barselau, an analyst in CBO's Budget Analysis Division, and Scott Laughery, an analyst in CBO's Health Analysis Division, at a meeting of CBO's Panel of Health Advisers.
This presentation reviews how CBO estimated the budgetary effects of three provisions of the 2022 reconciliation act related to prescription drugs: drug price negotiation in Medicare, the Medicare inflation rebate, and the redesign of the Medicare Part D benefit. CBO describes how recent developments affect the agency's assessment of the effects of each of those provisions and poses unanswered questions for which the agency would like the panel members' insights. CBO also comments on its ongoing efforts to understand the effects of the provisions on the development of new drugs.
